NAMS
NewAmsterdam Pharma·NASDAQ
--
--(--)
--
--(--)
6.64 / 10
Outperform
Analyst sentiment is overwhelmingly bullish with a 100% Buy rating from one analyst (Leonid Timashev, RBC Capital) and a historical win rate of 100%. Fund flow metrics score 7.74/10, indicating robust capital movement; however, large-cap inflows are only moderate (Large_inflow_ratio 0.524) while extra-large inflows are negative (Extra-large_inflow_ratio 0.446). This combination supports a cautiously optimistic view despite some institutional hesitation.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-21
InstitutionRBC Capital
Times predicted3
Historical Win Rate100.0%
Is money flowing into or out of NAMS?
- NAMS holds a Bullish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.64/10 (Outperform).
